Heidi Schwarzenbach

List of Publications by Year
in descending order

82	8,763	81900 39	66911 78
papers	citations	h-index	g-index

84	84	84	13485
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	MicroRNAs and their Implications in CD4+ T-cells, Oligodendrocytes and Dendritic Cells in Multiple Sclerosis Pathogenesis. Current Molecular Medicine, 2023, 23, 630-647.	1.3	4
2	Characterization of circulating molecules and activities in plasma of patients after allogeneic and autologous intraoral bone grafting procedures: a prospective randomized controlled clinical trial in humans. BMC Oral Health, 2022, 22, 24.	2.3	2
3	The History and Future of Basic and Translational Cell-Free DNA Research at a Glance. Diagnostics, 2022, 12, 1192.	2.6	5
4	Diagnostic and Prognostic Value of miR-16, miR-146a, miR-192 and miR-221 in Exosomes of Hepatocellular Carcinoma and Liver Cirrhosis Patients. Cancers, 2021, 13, 2484.	3.7	23
5	Exosomes in Immune Regulation. Non-coding RNA, 2021, 7, 4.	2.6	23
6	Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy. Scientific Reports, 2020, 10, 21562.	3.3	6
7	A novel assay for exosomal and cell-free miRNA isolation and quantification. RNA Biology, 2020, 17, 425-440.	3.1	10
8	Predictive value of exosomes and their cargo in drug response/resistance of breast cancer patients. , 2020, 3, 63-82.		4
9	Circulating Mitochondrial DNA is Linked to Progression and Prognosis of Epithelial Ovarian Cancer. Translational Oncology, 2019, 12, 1213-1220.	3.7	28
10	MicroRNA expression studies: challenge of selecting reliable reference controls for data normalization. Cellular and Molecular Life Sciences, 2019, 76, 3497-3514.	5.4	29
11	Characterization of circulating DNA in plasma of patients after allogeneic bone grafting. Clinical Oral Investigations, 2019, 23, 4243-4253.	3.0	15
12	MicroRNA Shuttle from Cell-To-Cell by Exosomes and Its Impact in Cancer. Non-coding RNA, 2019, 5, 28.	2.6	77
13	The current role of circulating biomarkers in non-muscle invasive bladder cancer. Translational Andrology and Urology, 2019, 8, 61-75.	1.4	11
14	Interplay of lncRNA H19/miRâ€675 and lncRNA NEAT1/miRâ€204 in breast cancer. Molecular Oncology, 2019, 13, 1137-1149.	4.6	84
15	Potential microRNA-related targets in clearance pathways of amyloid-Î²: novel therapeutic approach for the treatment of Alzheimerâ€™s disease. Cell and Bioscience, 2019, 9, 91.	4.8	29
16	Copy Number Variation Analysis on Cell-Free Serum DNA. Methods in Molecular Biology, 2019, 1909, 85-93.	0.9	3
17	The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder. World Journal of Urology, 2019, 37, 1785-1799.	2.2	18
18	Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients. , 2019, 2, 271-296.		9

#	Article	IF	Citations
19	Circulating non-coding RNAs in recurrent and metastatic ovarian cancer. , 2019, 2, 399-418.		2
20	Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Medicine, 2018, 16, 179.	5.5	134
21	Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients. Scientific Reports, 2018, 8, 12974.	3.3	59
22	Diagnosis, monitoring and prevention of exposure-related non-communicable diseases in the living and working environment: DiMoPEx-project is designed to determine the impacts of environmental exposure on human health. Journal of Occupational Medicine and Toxicology, 2018, 13, 6.	2.2	32
23	Exosomal micro<scp>RNA</scp>s as tumor markers in epithelial ovarian cancer. Molecular Oncology, 2018, 12, 1935-1948.	4.6	125
24	Detection and oncological impact of circulating tumor cells in bladder cancer patients with presence of copy number variations of circulating cell free DNA.. Journal of Clinical Oncology, 2018, 36, 495-495.	1.6	1
25	Methods for quantification and characterization of microRNAs in cell-free plasma/serum, normal exosomes and tumor-derived exosomes. Translational Cancer Research, 2018, 7, S253-S263.	1.0	5
26	Plasma microRNA signature is associated with risk stratification in prostate cancer patients. International Journal of Cancer, 2017, 141, 1231-1239.	5.1	40
27	Clinical Relevance of Circulating, Cell-Free and Exosomal microRNAs in Plasma and Serum of Breast Cancer Patients. Oncology Research and Treatment, 2017, 40, 423-429.	1.2	52
28	Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study. Oncotarget, 2017, 8, 56398-56407.	1.8	25
29	Implementing liquid biopsies into clinical decision making for cancer immunotherapy. Oncotarget, 2017, 8, 48507-48520.	1.8	63
30	Diagnostic relevance of circulating cell-free and exosomal microRNAs and long non-coding RNAs in blood of cancer patients. Laboratoriums Medizin, 2016, 40, 345-353.	0.6	2
31	Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Oncotarget, 2016, 7, 16923-16935.	1.8	207
32	Biological and Clinical Relevance of H19 in Colorectal Cancer Patients. EBioMedicine, 2016, 13, 9-10.	6.1	28
33	Circulating Cell-Free miR-373, miR-200a, miR-200b and miR-200c in Patients with Epithelial Ovarian Cancer. Advances in Experimental Medicine and Biology, 2016, 924, 3-8.	1.6	37
34	Novel Technology for Enrichment of Biomolecules from Cell-Free Body Fluids and Subsequent DNA Sizing. Advances in Experimental Medicine and Biology, 2016, 924, 165-169.	1.6	0
35	Clinical significance of miR-15 and miR-16 in ovarian cancer. Translational Cancer Research, 2016, 5, S50-S53.	1.0	9
36	Aberrant plasma levels of circulatingmiR-16, miR-107, miR-130aandmiR-146aare associated with lymph node metastasis and receptor status of breast cancer patients. Oncotarget, 2015, 6, 13387-13401.	1.8	88

#	Article	IF	Citations
37	The potential of circulating nucleic acids as components of companion diagnostics for predicting and monitoring chemotherapy response. Expert Review of Molecular Diagnostics, 2015, 15, 267-275.	3.1	12
38	The clinical relevance of circulating, exosomal miRNAs as biomarkers for cancer. Expert Review of Molecular Diagnostics, 2015, 15, 1159-1169.	3.1	77
39	Data Normalization Strategies for MicroRNA Quantification. Clinical Chemistry, 2015, 61, 1333-1342.	3.2	384
40	Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients. British Journal of Cancer, 2015, 113, 1358-1366.	6.4	110
41	Circulating DNA as biomarker in breast cancer. Breast Cancer Research, 2015, 17, 136.	5.0	89
42	Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget, 2014, 5, 9650-9663.	1.8	304
43	Differential regulation of MAGE-A1 promoter activity by BORIS and Sp1, both interacting with the TATA binding protein. BMC Cancer, 2014, 14, 796.	2.6	14
44	Clinical relevance of circulating cell-free microRNAs in cancer. Nature Reviews Clinical Oncology, 2014, 11, 145-156.	27.6	915
45	Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Breast Cancer Research and Treatment, 2014, 147, 61-68.	2.5	108
46	Tumor-Induced Osteoclast miRNA Changes as Regulators and Biomarkers of Osteolytic Bone Metastasis. Cancer Cell, 2013, 24, 542-556.	16.8	251
47	Deregulated Serum Concentrations of Circulating Cellâ€“Free MicroRNAs miR-17, miR-34a, miR-155, and miR-373 in Human Breast Cancer Development and Progression. Clinical Chemistry, 2013, 59, 1489-1496.	3.2	180
48	Circulating nucleic acids as biomarkers in breast cancer. Breast Cancer Research, 2013, 15, 211.	5.0	95
49	Circulating Mitochondrial DNA as Biomarker Linking Environmental Chemical Exposure to Early Preclinical Lesions Elevation of mtDNA in Human Serum after Exposure to Carcinogenic Halo-Alkane-Based Pesticides. PLoS ONE, 2013, 8, e64413.	2.5	49
50	Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast Cancer Research and Treatment, 2012, 134, 933-941.	2.5	148
51	Loss of Heterozygosity at Tumor Suppressor Genes Detectable on Fractionated Circulating Cell-Free Tumor DNA as Indicator of Breast Cancer Progression. Clinical Cancer Research, 2012, 18, 5719-5730.	7.0	63
52	LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival. BMC Cancer, 2012, 12, 325.	2.6	37
53	Low Levels of Cell-Free Circulating miR-361-3p and miR-625* as Blood-Based Markers for Discriminating Malignant from Benign Lung Tumors. PLoS ONE, 2012, 7, e38248.	2.5	66
54	Circulating nucleic acids and protease activities in blood of tumor patients. Expert Opinion on Biological Therapy, 2012, 12, S163-S169.	3.1	6

#	Article	IF	Citations
55	Circulating Tumor Cells and Circulating Tumor DNA. Annual Review of Medicine, 2012, 63, 199-215.	12.2	411
56	Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. Molecular Oncology, 2011, 5, 281-291.	4.6	97
57	Monitoring of Loss of Heterozygosity in Serum Microsatellite DNA Among Patients with Gastrointestinal Stromal Tumors Indicates Tumor Recurrence. Journal of Surgical Research, 2011, 169, 31-35.	1.6	17
58	Cell-free nucleic acids as biomarkers in cancer patients. Nature Reviews Cancer, 2011, 11, 426-437.	28.4	2,372
59	Impact of Physical Activity and Doping on Epigenetic Gene Regulation. Drug Testing and Analysis, 2011, 3, 682-687.	2.6	12
60	Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease. Molecular BioSystems, 2011, 7, 2848.	2.9	61
61	Genomic profiling of cell-free DNA in blood and bone marrow of prostate cancer patients. Journal of Cancer Research and Clinical Oncology, 2011, 137, 811-819.	2.5	25
62	Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression. BMC Cancer, 2011, 11, 4.	2.6	81
63	Loss of heterozygosity proximal to the M6P/IGF2R locus is predictive for the presence of disseminated tumor cells in the bone marrow of ovarian cancer patients before and after chemotherapy. Genes Chromosomes and Cancer, 2011, 50, 598-605.	2.8	7
64	Impact of platinumâ€based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients. International Journal of Cancer, 2011, 128, 2572-2580.	5.1	71
65	Predictive diagnostics in colorectal cancer: impact of genetic polymorphisms on individual outcomes and treatment with fluoropyrimidine-based chemotherapy. EPMA Journal, 2010, 1, 485-494.	6.1	4
66	Promoter- and cell-specific epigenetic regulation of CD44, Cyclin D2, GLIPR1 and PTEN by Methyl-CpG binding proteins and histone modifications. BMC Cancer, 2010, 10, 297.	2.6	31
67	Molecular analysis of the polymorphisms of thymidylate synthase on cellâ€free circulating DNA in blood of patients with advanced colorectal carcinoma. International Journal of Cancer, 2010, 127, 881-888.	5.1	10
68	Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Research, 2010, 12, R90.	5.0	374
69	Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer. Breast Cancer Research, 2009, 11, R71.	5.0	53
70	Cell-free Tumor DNA in Blood Plasma As a Marker for Circulating Tumor Cells in Prostate Cancer. Clinical Cancer Research, 2009, 15, 1032-1038.	7.0	221
71	Detection and Monitoring of Cellâ€Free DNA in Blood of Patients with Colorectal Cancer. Annals of the New York Academy of Sciences, 2008, 1137, 190-196.	3.8	158
72	Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer. BJU International, 2008, 102, 253-258.	2.5	38

#	Article	IF	Citations
73	Identification of Loss of Heterozygosity on Circulating Free DNA in Peripheral Blood of Prostate Cancer Patients: Potential and Technical Improvements. Clinical Chemistry, 2008, 54, 688-696.	3.2	40
74	Methyl-CpG Binding Domain Proteins and Their Involvement in the Regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 Gene Promoters. Molecular Cancer Research, 2007, 5, 749-759.	3.4	40
75	Microsatellite Analysis in Serum DNA as a Diagnostic Tool for Distinction of Patients With Unknown Pancreatic Masses. Diagnostic Molecular Pathology, 2007, 16, 174-178.	2.1	1
76	A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer. Breast Cancer Research, 2007, 9, R66.	5.0	26
77	Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer. International Journal of Cancer, 2007, 120, 1465-1471.	5.1	54
78	Similar patterns of loss of heterozygosity in serum of adenocarcinoma of the distal oesophagus and the cardia in early diagnosis. Anticancer Research, 2007, 27, 477-81.	1.1	3
79	Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer. BJU International, 2006, 98, 544-548.	2.5	104
80	Comparison of Genetic Alterations Detected in Circulating Microsatellite DNA in Blood Plasma Samples of Patients with Prostate Cancer and Benign Prostatic Hyperplasia. Annals of the New York Academy of Sciences, 2006, 1075, 222-229.	3.8	37
81	Promoter Demethylation and Histone Acetylation Mediate Gene Expression of MAGE-A1, -A2, -A3, and -A12 in Human Cancer Cells. Molecular Cancer Research, 2006, 4, 339-349.	3.4	163
82	Detection and Characterization of Circulating Microsatellite-DNA in Blood of Patients with Breast Cancer. Annals of the New York Academy of Sciences, 2004, 1022, 25-32.	3.8	54